Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis

Figure 2

16 K hPRL increases endothelial SPRY1 expression in vivo in a mouse xenograft tumor model. Effect of 16 K hPRL on tumor growth. Representative data of 2 independent experiments are shown. A. Western blotting performed on protein extracts from tumors (100 μg protein) with an anti-hPRL polyclonal antibody, recombinant 16 K hPRL (100 ng, 16 K hPRL) was used as control. B. Tumor growth curves of HCT116 tumor cells in mice treated with 16 K-Ad or Null-Ad. C. Agarose electrophoresis of products of end-point PCR performed with human-specific (h) or mouse-specific (m) primers on cloned full-length mouse or human SPRY1 or PPIA (cyclophilin A) cDNA. D. Analysis of Spry1 mRNA expression by qRT-PCR using mouse-specific primers in RNA extracted from tumors. Data were normalized with respect to the mouse ppia transcript level. E. Agarose electrophoresis of products of end-point PCR performed with human-specific or mouse-specific primers on RNA extracted from tumors harvested from nude mice injected with HCT116 tumor cells and treated with 16 K-Ad or control Null-Ad adenovirus. F. The SPRY1 mRNA expression measured by qRT-PCR in RNA extracted from HCT116 cells after 2 or 4 h of treatment with 16 K hPRL (10 nM). The data were normalized to the PPIA transcript level. D, F. Data are mean fold change + SD (n = 3), *: significant at p < 0.05. The results shown are representative of at least three independent experiments.

Back to article page